Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | PGK1 | P00558 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700580 | 0.96 | LMNA (0.64) | LMNAALDH1A1PGK1CA12CA9 | |
| SCHEMBL13892936 | 0.81 | LMNA (0.59) | LMNAALDH1A1PGK1CA12CA9 | |
| SCHEMBL5857203 | 0.78 | LMNA (0.68) | LMNAALDH1A1PGK1CA12CA9 | |
| SCHEMBL13883301 | 0.77 | LMNA (0.56) | LMNAALDH1A1PGK1CA12CA9 | |
| SCHEMBL14018693 | 0.77 | ALDH1A1 (0.71) | LMNAALDH1A1PGK1CA12CA9 | |
| SCHEMBL6497225 | 0.75 | LMNA (0.63) | LMNAALDH1A1PGK1CA12CA9 | |
| SCHEMBL11210425 | 0.74 | LMNA (0.41) | LMNAALDH1A1PGK1MAPTKMT2A | |
| SCHEMBL10421505 | 0.74 | LMNA (1.00) | LMNAALDH1A1PGK1CA12CA9 | |
| SCHEMBL4704291 | 0.74 | MAPT (0.56) | LMNAALDH1A1MAPTKMT2ATDP1 | |
| SCHEMBL2073967 | 0.74 | RAB9A (0.56) | LMNAALDH1A1MAPTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439236-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1219622-B1 | Pharmaceutical compositions for CNS and other disorders | PFIZER PROD INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-6881734-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6809094-B2 | N-FUSED HETERCYCLO-1,4- OR -1,5- DIAZABICYCLO DERIVATIVES; NICOTINIC RECEPTOR AGONISTS; CENTRAL NERVOUS SYSTEM (CNS) | PFIZER INC | 2004-10-26 | — | — | US | disclosed |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | O'NEILL BRIAN THOMAS (US) | 2002-07-04 | — | — | US | disclosed |
| EP-1219622-A2 | Pharmaceutical compositions for CNS and other disorders | Pfizer Products Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA10, CHRNA5 | LMNA 1441/4885ALDH1A1 1685/4885PGK1 2982/4885 |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | LMNA 1839/4885ALDH1A1 1704/4885PGK1 3270/4885 |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | LMNA 1839/4885ALDH1A1 1704/4885PGK1 3270/4885 |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | C1QBP, BCHE, BDNF | LMNA 3370/4885ALDH1A1 2419/4885PGK1 3531/4885 |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | LMNA 1839/4885ALDH1A1 1704/4885PGK1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.